Floor Backes

Trials

Studies that name Floor Backes as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 17:56 UTC. Open this list on ClinicalTrials.gov

• Early Ph1
  NCT05415709 · Hyperthermic Intraperitoneal Chemotherapy With Cisplatin During Surgery or Cisplatin Before Surgery for the Treatment of Stage III or IV Ovarian, Fallopian Tube or Peritoneal Cancer

  Ohio State University Comprehensive Cancer Center · active not recruiting · Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Mucinous Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma · principal investigator
• Early Ph1
  NCT04906382 · Tislelizumab for the Treatment of Recurrent Mismatch Repair Deficient Endometrial Cancer

  Floor Backes, MD · terminated · Lynch Syndrome, Recurrent Endometrial Carcinoma, Recurrent Endometrial Clear Cell Adenocarcinoma · principal investigator
• Ph2
  NCT04781088 · Lenvatinib, Pembrolizumab, and Paclitaxel for Treatment of Recurrent Endometrial, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

  Floor Backes, MD · active not recruiting · Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma · principal investigator
• Ph3
  NCT04214067 · Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to the Usual Radiation Treatment for Newly Diagnosed Early Stage High Intermediate Risk Endometrial Cancer

  National Cancer Institute (NCI) · active not recruiting · Endometrial Endometrioid Adenocarcinoma, Stage I Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8, Stage II Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8 · principal investigator
• Ph1
  NCT03552471 · Mirvetuximab Soravtansine and Rucaparib Camsylate in Treating Participants With Recurrent Endometrial, Ovarian, Fallopian Tube or Primary Peritoneal Cancer

  Ohio State University Comprehensive Cancer Center · completed · BRCA1 Gene Mutation, BRCA2 Gene Mutation, Folate Receptor Alpha Positive · principal investigator
• Ph1
  NCT02788708 · Lenvatinib and Weekly Paclitaxel for Patients With Recurrent Endometrial or Ovarian Cancer

  Floor Backes · completed · Fallopian Tube Carcinoma, Recurrent Ovarian Cancer, Primary Peritoneal Carcinoma · principal investigator
• N/A
  NCT01818739 · Lymph Node Mapping in Patients With Endometrial Cancer

  Ohio State University Comprehensive Cancer Center · completed · Endometrial Cancer · principal investigator

Grants

NIH projects from RePORTER, fetched 2026-11-11 17:56 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.

• Gynecologic cancer care: Improving clinical trial enrollment through molecular matching with targeted therapies and improving access to care and research
  R50CA287196 · NCI · OHIO STATE UNIVERSITY · fiscal years 2024 to 2026 · $132,015 awarded in 2026
  Same name and institution; not confirmed by an ID

NIH grants that fund their trials

These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.

• NRG Oncology Network Group Operations Center
  U10CA180868 · NCI · NRG ONCOLOGY FOUNDATION, INC. · PI Quynh-Thu Xuan Le, ROBERT S. MANNEL, NORMAN WOLMARK · fiscal years 2014 to 2026
  Named on NCT04214067